News >

FDA Extends Review Period for Selinexor in Myeloma

Jason M. Broderick @jasoncology
Published: Friday, Mar 15, 2019

Sharon Shacham, PhD, MBA

Sharon Shacham, PhD, MBA

The FDA has added 3 months to the review period for a new drug application (NDA) for selinexor for the treatment of patients with penta-refractory multiple myeloma, making the new action date July 6, 2019.

In February, however, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 8 to 5 against accelerated approval of the NDA, recommending delaying a decision on the drug until results are available from the pivotal phase III BOSTON trial.


Following the ODAC meeting, the FDA, which is not required to follow the ODAC recommendation, requested further information from Karyopharm as an amendment to the NDA.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x